How effective is semaglutide, really? What the evidence says

What the trial numbers actually mean for you

The 15% average from STEP 1 is a population figure. For an 18-stone adult, that translates to roughly 2.5 stone over a year and a half. Some participants lost considerably more; others less. Results spread around the average, that is what averages do. The trial ran for 68 weeks and included 1,961 adults with a BMI of 30 or above, or 27 and above with a weight-related condition such as high blood pressure or raised cholesterol.

The more recent approval of the 7.2mg dose changes the picture somewhat. The MHRA's April 2026 approval of the dedicated 7.2mg single-dose pen followed trial data reporting around 20.7% average weight loss over 72 weeks, meaningfully higher than the 2.4mg figure. That dose is licensed only for adults with a BMI of 30 or above, and titration still starts at 0.25mg, stepping up under clinical guidance. If you want a fuller picture of how Wegovy compares at different doses, our page on how effective Wegovy is for weight loss covers the trajectory in more detail.

One practical point worth knowing: appetite suppression tends to be strongest in the first few months. People often describe noticing food less, feeling full on smaller portions, and losing the urge to snack. That effect is real and pharmacological, not willpower. But it is not uniform, and individual response varies in ways that are not yet fully predictable.

The variables that influence your personal result

Semaglutide is effective, but the size of that effect shifts depending on several things. Starting BMI matters: people with higher baseline weights often see larger absolute losses, though percentage reductions can be similar across the range. Presence of type 2 diabetes blunts the response somewhat, trial data consistently show slightly smaller losses in people with diabetes compared to those without, because insulin resistance and glucose metabolism interact with how the body uses stored energy.

Adherence to the titration schedule is significant too. The dose escalation from 0.25mg upward exists partly to manage gastrointestinal side effects, and patients who tolerate the schedule fully tend to reach the maintenance dose more reliably. Those who stay on the 1mg or 1.7mg level for extended periods because of nausea may see a slower curve. Our page on making Wegovy more effective looks at the lifestyle and routine factors that support the medicine's action.

Protein intake, strength-based activity and adequate sleep all appear to support better outcomes alongside GLP-1 treatment, though personal plans should be agreed with your prescriber or a dietitian, not drawn from general guidance. The medicine is part of the picture, not all of it. If you are earlier in the titration journey, our page covering what to expect at the 500 mcg semaglutide stage explains how that introductory dose fits into the broader schedule.

How long does semaglutide stay effective?

The STEP 1 data and subsequent real-world evidence both point to a consistent pattern: weight loss accelerates in the first 16–20 weeks, then continues at a slower rate, then plateaus. That plateau is normal and does not mean the medicine has stopped working. It reflects the body reaching a new equilibrium.

What happens when treatment stops is equally well documented. When semaglutide is discontinued without sustained lifestyle changes in place, a significant proportion of lost weight returns over the following year. This is not a failure of the medicine; it reflects the chronic nature of obesity as a condition. NICE's guidance on semaglutide (Wegovy) under TA875 acknowledges this, which is why NHS access is tied to specialist weight management services with ongoing support. Privately, continuation is a clinical decision reviewed at each repeat.

The pen itself needs to be stored in the fridge between uses, most people keep it in the door shelf, which keeps the routine visible and consistent. If travel is involved, the SmPC and patient information leaflet set out the room-temperature window; always check those rather than working from memory.

Semaglutide versus the alternatives: where it sits

For most of the last five years, semaglutide at 2.4mg was the strongest GLP-1 option licensed in the UK for weight management. That picture has shifted. Tirzepatide (Mounjaro), a dual GIP and GLP-1 agonist, produced greater average weight loss than semaglutide 2.4mg in the SURMOUNT-5 head-to-head trial published in 2025, the first direct comparison at scale. Whether that difference matters clinically for a given person is a separate question, and the SURMOUNT-5 authors were careful to note that individual responses overlap considerably.

The 7.2mg semaglutide dose narrows the gap, and our page on which semaglutide formulation is most effective sets out how the doses and formats compare for people trying to weigh up their options. And from summer 2026, the oral semaglutide tablet (Wegovy tablets, approved by the MHRA on 11 June 2026 as the first oral GLP-1 for weight management in the UK) adds another option: a once-daily tablet with an average loss of around 13.6% over 64 weeks in the OASIS 4 trial. For people weighing up whether the injectable is worth it, our page looking at whether Wegovy is actually effective sets out the evidence in plain terms. You can also read more about the injectable option and how it compares on the Wegovy overview page, or explore the broader range of approaches on our weight loss treatments overview.

Deciding which medicine best fits your situation is exactly what a prescriber works through with you. If you'd like to check whether you'd be eligible to start, our free consultation connects you with a GPhC-registered Independent Prescriber who reviews your details the same day.